The deal with Roche was a key element in ThromboGenics' corporate strategy, and has allowed the Company to focus on developing the other attractive products in its pipeline, particularly its lead product, microplasmin. The upfront payment from Roche has also provided a significant portion of the funds needed for the microplasmin Phase III program, which will evaluate the drug in a number of back of the eye disease indications.
TB-402 (Anti-Factor VIII) - A Unique, Long-acting Anti-coagulant
ThromboGenics is developing TB-402 in collaboration with BioInvent International. TB-402 is a novel human antibody which partially blocks Factor VIII, an essential blood clotting factor. TB-402 is being developed as an anticoagulant for the treatment and prevention of deep vein thrombosis (DVT) and atrial fibrillation. It is anticipated that TB-402 will be a novel, safe, and affordable anticoagulant, providing extended activity with a single dose, with ease of administration and compliance superior to alternative anticoagulants.
The Phase I interaction studies, which were successfully completed in the second quarter of 2008, have shown that TB-402 has the potential to be a safe and well controlled treatment for diseases where the prevention of blood clots is imperative. As a result of the encouraging results from these studies, TB-402 is expected to begin its Phase II clinical development by the end of 2008.
ThromboGenics will provide a further update when the Company reports
its 2008 Full Year Results on 12th March, 2009.
For further information please contact:
Patrik De Haes, CEO, Tel : +32-16-75-13-10,
Chris Buyse, CFO, Tel : +32-16-75-13-10,
|SOURCE ThromboGenics NV|
Copyright©2008 PR Newswire.
All rights reserved